Please check your internet connection and try again.
# Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep
## Overview
Taborvolhep is a nucleoside analog reverse transcriptase inhibitor (NRTI) used in the treatment of chronic hepatitis B virus (HBV) infection. It works by inhibiting HBV DNA polymerase, thus reducing viral replication.
## Primary Indications
Chronic hepatitis B virus (HBV) infection.
## Adult Dosing
The recommended dose is 0.5 mg orally once daily.
## Pediatric Dosing
Dosing in pediatric patients is not well-established. Consult specialized literature or local protocols.
## Dose Adjustments
* **Renal Impairment:** Dose adjustment is required based on creatinine clearance (CrCl).
* CrCl 50-80 mL/min: 0.5 mg every other day.
* CrCl 30-49 mL/min: 0.25 mg every other day.
* CrCl 10-29 mL/min: 0.25 mg twice weekly.
* CrCl <10 mL/min or on hemodialysis/continuous ambulatory peritoneal dialysis: 0.25 mg twice weekly.
* **Hepatic Impairment:** No dose adjustment is typically needed in patients with hepatic impairment, but caution is advised.
## Contraindications
* Hypersensitivity to taborvolhep or any of its components.
* Severe renal impairment (CrCl < 10 mL/min) not on dialysis may warrant extreme caution or avoidance.
## Adverse Effects
Common adverse effects include headache, nausea, diarrhea, fatigue, and insomnia. More serious adverse effects can include lactic acidosis and severe hepatomegaly with steatosis. Lactic acidosis is a medical emergency and can be fatal.
## Key Drug Interactions
* **Didanosine:** Concomitant use may increase the risk of pancreatitis and peripheral neuropathy.
* **Ribavirin:** Concurrent use is generally not recommended due to potential for synergistic toxicity.
* **Drugs that prolong the QT interval:** Caution advised.
## Monitoring
* **Renal Function:** Monitor serum creatinine and CrCl regularly, especially in patients with pre-existing renal impairment or those taking other nephrotoxic agents.
* **Liver Function:** Monitor ALT, AST, bilirubin, and alkaline phosphatase levels regularly to detect hepatotoxicity.
* **Viral Load:** Monitor HBV DNA levels periodically to assess treatment efficacy.
* **Lactic Acidosis:** Educate patients on signs and symptoms (e.g., abdominal pain, difficulty breathing, nausea, vomiting, rapid breathing).
## Clinical Pearls
* Taborvolhep should be taken on an empty stomach, at least 2 hours before or 2 hours after a meal.
* Discontinuation of therapy can lead to exacerbation of hepatitis B. If treatment is stopped, patients should be monitored closely for signs of hepatitis flares.
* The potential for developing resistance should be considered.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines before making any clinical decisions.
